Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
-
Published:2021-04-27
Issue:3
Volume:73
Page:658-666
-
ISSN:1355-008X
-
Container-title:Endocrine
-
language:en
-
Short-container-title:Endocrine
Author:
Chiloiro Sabrina,Giampietro Antonella,Visconti Felicia,Rossi Laura,Donfrancesco Federico,Fleseriu Cara M.,Mirra Federica,Pontecorvi Alfredo,Giustina Andrea,Fleseriu Maria,De Marinis Laura,Bianchi Antonio
Abstract
Abstract
Introduction
Disorders of glucose metabolism are a serious acromegaly comorbidity and may be differently impacted by medical treatments of acromegaly. In this retrospective longitudinal multicenter study, we investigated the outcome of glucose metabolism and its predictors in patients treated with Pasireotide LAR (PAS-LAR) alone or in combination with Pegvisomant (PAS-LAR + Peg-V).
Subjects and methods
Acromegaly patients treated continously with PAS-LAR or PAS-LAR + Peg-V for at least 6 months.
Results
Forty patients (25 females, 15 males) were enrolled. At last visit, 27/40 patients (67.5%) reached biochemical control of acromegaly. Overall, glucose metabolism improved in 3 (all in PAS-LAR + Peg-V; 7.5%), worsened in 26 (65%) and remained unchanged in 11 patients (27.5%). Glucose metabolism worsened in 25 patients (73.5%) treated with PAS-LAR and in a single patient (16.7%) treated with PAS-LAR + Peg-V (p < 0.001). Among patients treated with Pas-LAR alone, GH at baseline was higher in those with worsening of glucose metabolism (p = 0.04) as compared to those with stable glucose status. A significantly higher reduction of HbA1c was observed in patients treated with PAS-LAR + Peg-V, as compared with those treated with PAS-LAR alone (p = 0.005).
Conclusions
Our data confirmed that glucose metabolism in patients treated with PAS-LAR is often worsened, and may be predicted by entity of baseline GH hypersecretion and by the dose of PAS-LAR. Moreover, our data, although limited by small numbers, may suggest that the combination treatment PAS-LAR + Peg-V can improve glucose homeostasis in selected patients.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference45 articles.
1. Melmed, S. Pituitary-tumor endocrinopathies. N Engl J Med. (2020). https://doi.org/10.1056/NEJMra1810772 2. Gadelha, M.R., Kasuki, L., Lim, D.S.T., Fleseriu M. Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr Rev. (2019). https://doi.org/10.1210/er.2018-00115 3. D. Solari, R. Pivonello, C. Caggiano, E. Guadagno, C. Chiaramonte, G. Miccoli, L.M. Cavallo, M. Del Basso De Caro, A. Colao, P. Cappabianca, Pituitary adenomas: what are the key features? what are the current treatments? where is the future taking us? World Neurosurg. 127, 695–709 (2019) 4. S.Ç. Altuntaş, M. Evran, M. Sert, T. Tetiker, Markers of metabolic syndrome in patients with pituitary adenoma: a case series of 303 patients. Horm Metab Res. 51, 709–13 (2019) 5. A. Mestron, S.M. Webb, R. Astorga, P. Benito, M. Catala, S. Gaztambide, J. Gomez, I. Halperin, T.M. Morante, B. Moreno, G. Obiols, P. de Pablos, C. Paramo, A. Pico, E. Torres, C. Varela, J.A. Vazquez, J. Zamora, M. Albareda, M. Gilabert, Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol. 151, 439–46 (2004)
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|